Literature DB >> 2700221

Oral and gastrointestinal candidosis: prophylaxis during immunosuppressive therapy.

A G Prentice.   

Abstract

Patients with acute leukaemia and malignant lymphomas often are severely affected by fungal infections. There is in particular growing concern about disseminated candidosis. Oral, gastrointestinal and systemic candidosis seem to be closely linked. Predisposing factors are damaged mucosal barriers due to chemotherapy, protracted periods of neutropenia, and prolonged use of antibiotics and steroids. Oropharyngeal candidosis is very frequent. This can be prevented or controlled by the application of topical antifungals such as nystatin. The systemic application of antifungals is an alternative for patients who do not respond. Both oral ketoconazole and intravenous amphotericin B have been proven effective. Candida oesophagitis is also an important problem. Oral nystatin suspension can be helpful in mild cases. In others oral ketoconazole and intravenous amphotericin B have to be used. A whole range of measures has to be taken to prevent spread of the disease, i.e. H2-antagonists should be used only if definitely needed. Specific antifungal prophylaxis has also been discussed. Oral amphotericin B seems to be helpful. The azole itraconazole might be especially promising.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2700221     DOI: 10.1111/j.1439-0507.1989.tb02309.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  2 in total

1.  Candida esophagitis complicated by an esophago-airway fistula: report of a case.

Authors:  Ryu Kanzaki; Masahiko Yano; Ko Takachi; Shingo Ishiguro; Masaaki Motoori; Kentaro Kishi; Isao Miyashiro; Osamu Ishikawa; Shingi Imaoka
Journal:  Surg Today       Date:  2009-11-01       Impact factor: 2.549

2.  Topical nystatin prophylaxis: a likely viable measure for reducing impact of candidemia in neurosurgical patients with early tracheostomy intubation.

Authors:  Giancarlo Ceccarelli; Simone Giuliano; Marco Falcone; Mario Venditti
Journal:  Crit Care       Date:  2013-02-18       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.